Objective To describe disease course, histopathology, and outcomes for infants with atypical presentations of alveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV) who underwent bilateral lung transplantation.
A lveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV, OMIM 265380) is a rare developmental lung disorder with nearly uniform mortality in the first month of life. 1, 2 Neonates with classic ACDMPV are typically born at term and present with progressive, hypoxemic respiratory failure and severe, refractory pulmonary hypertension within the first few hours after birth. Extrapulmonary anomalies are common and typically involve the gastrointestinal, cardiac, and/or genitourinary systems. 3 Although there are a few case reports of infants with atypical presentations of ACDMPV beyond the newborn period or with less fulminant neonatal disease [4] [5] [6] [7] [8] [9] (Table I ; available at www.jpeds.com), the clinical, histopathologic, and genetic factors that contribute to delayed or less severe presentations are not well-characterized.
The diagnosis of ACDMPV is made by histologic examination of lung tissue. 10 Owing to the high neonatal mortality rate, many infants are diagnosed at autopsy, although a steady increase in diagnosis by lung biopsy has recently been observed. 3 The histopathologic features diagnostic of ACDMPV include deficient capillarization of the alveoli (decreased numbers of capillaries with displacement from alveolar epithelium), malposition of pulmonary veins adjacent to small pulmonary arteries within the same bronchovascular bundle (BVB), and medial hypertrophy of small pulmonary arteries and arterioles. Lobular maldevelopment with deficient alveolarization and lymphangiectasis are also commonly observed. 1, [11] [12] [13] Although it has been speculated that infants with delayed or less fulminant (atypical) presentations may have nonuniform distribution of disease that does not involve the entire lung, less abnormal density and placement of capillaries, or more normal lobular development, 5, 14, 15 limited information regarding the lung histopathology of these infants is available and often from only a single biopsy site.
Although the outcomes after bilateral lung transplant in infants with end-stage lung disease owing to genetic disorders of surfactant metabolism, interstitial lung disease (ILD), and pulmonary vascular disease have been reported, 16 the longterm outcomes of patients transplanted after atypical presentation of ACDMPV presentation have not been reported. Herein we report clinical data and histologic characterization from the largest series of infants with atypical presentations of ACDMPV who underwent lung transplantation.
Methods
Through a search of the St. Louis Children's Hospital/ Washington University School of Medicine Pediatric Lung Transplantation database, we identified 6 infants with atypical presentations of ACDMPV admitted over an 18-year period (1998-2016) who underwent bilateral lung transplantation. We obtained informed consent from parents of all infants and children and this study was approved by the Human Research Protection Office at Washington University. We reviewed clinical history, results from echocardiogram, cardiac catheterization, and chest computed tomography (CT), explant histology, and post-transplant course. We used Sanger sequencing to identify mutations in FOXF1 as described previously. 17 We analyzed genomic copy number variants (CNVs) using array comparative genomic hybridization with custom-designed 16q24.1 region-specific 3_720 K microarrays (Roche NimbleGen, Madison, Wisconsin). 17 A pediatric pathologist with expertise in childhood ILD and the diagnostic features of ACDMPV reviewed all explants. At least 2 sections from each lobe of the explant were reviewed for each subject (median number of sections per explant, 22; range, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Explant histology was compared with autopsy histology from 3 infants with classic ACDMPV and genetic defects of FOXF1 (2 with missense point mutations and 1 with a CNV deletion upstream of FOXF1). ACDMPV histologic criteria were characterized for each explant. 15, 18 Microscopic observations of alveolar capillaries were made on fields of congested, noncollapsed lung, in which architecture and capillaries were well-visualized. Findings of deficient capillarization of alveoli were described as "diffuse" (present throughout all fields, with difficulty in identifying normal capillarization in most fields), "mixed" (mixture of both normal and deficient capillarization throughout lung), and "focal" (predominantly normal, with focal areas of deficient capillarization). Findings of pulmonary vein malposition adjacent to small arteries were described as "extensive" (readily identified throughout the lung, with malposition in the majority of BVBs), "patchy" (identified throughout the lung, but in fewer than onehalf of BVBs), and "focal" (present, but in a minority of BVBs and not readily identified). Assessment of malposition of pulmonary veins did not include BVBs with tangential orientation in which a vein could not be excluded. Findings of medial hypertrophy of small arteries and arterioles were graded "mild," "moderate," or "severe," ranging from mild medial thickening to occlusive lesions. Lobular maldevelopment with deficient alveolarization was noted based on the presence of enlarged alveoli with apparent decrease in numbers of alveoli and was described as "present," "suggestive" (areas suggestive of deficient alveolarization), or "not suggestive." Lymphangiectasis was characterized as primarily involving the interlobular septae or involving both the interlobular septae and the BVBs.
Infant 1
A term male infant developed tachypnea at birth, was treated with oxygen, and then discharged home on room air (Table II) . He was also noted to have an inguinal hernia at birth. During the first few months of life, he experienced several episodes of pulmonary congestion attributed to upper respiratory tract infections before presenting on day of life (DOL) 109 with respiratory distress and severe pulmonary hypertension that required mechanical ventilation, vasopressor support, pulmonary vasodilators, and venoarterial extracorporeal membrane oxygenation for 8 days. He remained mechanically ventilated until bilateral lung transplant on DOL 139. He did well posttransplant for several years before developing bronchiolitis obliterans that led to a second transplant at 5 years of age. Two months after his second transplant, he developed progressive renal failure and died.
Infant 2
A term male infant developed neonatal respiratory distress and was treated with supplemental oxygen and continuous positive airway pressure on DOL 2. An echocardiogram demonstrated pulmonary hypertension. He was also noted to have nonobstructive posterior urethral valves. Owing to persistent oxygen requirement at 1 month of age, he underwent open lung biopsy, which was diagnostic for ACDMPV. At 2 months of age, a cardiac catheterization demonstrated suprasystemic right heart pressures that were mildly responsive to inhaled nitric oxide. He was discharged home on nasal cannula oxygen (0.5 L/minute) and nitric oxide (0.5 L/minute; estimated 5 parts per million). His oxygen and nitric oxide requirements gradually increased, and his pulmonary hypertension worsened, prompting bilateral lung transplantation at 21 months of age. He did well until 4 years of age, when he required a second transplant for chronic lung allograft dysfunction owing to rejection. He is alive at 16 years of age with bronchiolitis obliterans. Most recent (15 years) spirometry revealed forced Volume 194 • March 2018 expiratory volume in 1 second (FEV1) of 31% predicted, forced vital capacity (FVC) of 40% predicted, and FEV1/FVC of 68% indicating airflow obstruction (no response in FEV1 to bronchodilator therapy). Total lung capacity (TLC) was 2.29 L (60% predicted) and the residual volume (RV) was 0.99 L (111% predicted) with an RV/TLC of 43%, indicating air trapping. Diffusing capacity of the lungs for carbon monoxide was 67% predicted.
Infant 3
A female infant born at 36 weeks of gestation had no neonatal respiratory symptoms or congenital anomalies, but had a male sibling who died after lung transplantation for ACDMPV. She presented on DOL 71 with respiratory distress, cyanosis, and pulmonary hypertension by echocardiogram and was treated with mechanical ventilation, vasopressor support, and pulmonary vasodilators. She required mechanical ventilation until undergoing transplantation on DOL 159 and is alive with normal lung function at 14 years of age. Most recent (age 14 years) spirometry was essentially normal (FEV1 90% of predicted, FVC 86% of predicted, and FEV1/FVC 90%). TLC was 4.66 L (110% predicted) and RV was 1.71 L (154% predicted) with an RV/TLC ratio of 37%, suggestive of mild air trapping. The diffusing capacity of the lungs for carbon monoxide was normal.
Infant 4
A late preterm female infant born at 34 weeks of gestation developed abdominal distension and intestinal dysmotility on DOL 3 that resolved during a 17-day hospitalization in the neonatal intensive care unit. She did not have respiratory symptoms and remained on room air throughout her course in the neonatal intensive care unit. An echocardiogram on DOL 20 showed no evidence of pulmonary hypertension. On DOL 67, she presented with severe respiratory distress, shock, and cardiopulmonary arrest, and resuscitation included intubation, mechanical ventilation, oxygen, and nitric oxide. A cardiac catheterization demonstrated suprasystemic right heart pressures that were mildly responsive to inhaled nitric oxide. An open lung biopsy was diagnostic for ACDMPV. She remained mechanically ventilated and underwent bilateral lung transplantation on DOL 159. She developed bronchiolitis obliterans and died at 9 years of age.
Infant 5
This previously reported late preterm female infant born at 34 weeks of gestation was healthy at birth without respiratory symptoms. 19 On DOL 24 she was briefly hospitalized for apnea that was attributed to gastroesophageal reflux and did not recur. On DOL 92, she was hospitalized for dehydration secondary to diarrhea and was found to be hypoxemic. An echocardiogram demonstrated pulmonary hypertension. She was treated with supplemental oxygen via nasal cannula and sildenafil until DOL 273, when an open lung biopsy was diagnostic for ACDMPV. After the biopsy, she required venoarterial extracorporeal membrane oxygenation before transitioning to support from a paracorporeal lung assist device. 19 She underwent bilateral lung transplantation on DOL 286 and is alive at 6 years of age. Most recent (6 years) spirometry was normal (FEV1 96% of predicted, FVC 105% of predicted, and FEV1/FVC 83%). The TLC was 1.90 L (94% of predicted), RV was 0.51 L (69% of predicted), and RV/TLC was 27%. The diffusing capacity of the lungs for carbon monoxide was normal.
Infant 6
This term female infant had transient tachypnea of the newborn with possible pneumonia. 17 An echocardiogram revealed a patent ductus arteriosus without evidence of pulmonary hypertension. She was discharged from the neonatal intensive care unit on supplemental oxygen on DOL 17, which was continued until DOL 21. Over the next 5 months, she had poor weight gain and persistent retractions. She presented with respiratory distress and hypoxemia on DOL 212 during travel at high altitude. Cardiac catheterization demonstrated near systemic right heart pressures that were responsive to inhaled nitric oxide. Open lung biopsy was diagnostic of ACDMPV. She was gradually weaned off supplemental oxygen and nitric oxide and was discharged on DOL 249 on sildenafil and furosemide. On DOL 423, she developed an upper respiratory tract infection with coronavirus and progressive hypoxemic respiratory failure and required venovenous extracorporeal membrane oxygenation. She improved, was extubated, and received noninvasive positive pressure ventilation until bilateral lung transplantation on DOL 464. During the 3 months after the transplant, she had recurrent episodes of respiratory failure of unclear etiology and died at 18 months of age.
FOXF1 Sequencing and Assessment of CNVs
We obtained DNA from peripheral blood from 5 subjects (subjects 2-6). DNA was not available for subject 1. Two subjects had apparent nonmosaic missense variants in FOXF1 (c.146C>A: p.P49Q [subject 2] and c.377C>T: p.P126L [subject 4]) 3 (Table III) . Both variants are novel and not present in the Exome Aggregation Consortium database (exac.broadinstitute.org, Cambridge, MA) 20 and are predicted to be deleterious by in silico algorithms including SIFT, polyphen, LRT, mutation taster, GERP++, and PhyloP in ANNOVAR (annovar.openbioinformatics.org) 21 and CADD (cadd.gs.washington.edu/). 22 Subject 6 had an apparent nonmosaic 1.5-Mb CNV deletion mapping 306 kb upstream to FOXF1 that removed 26 kb of the proximal portion of the FOXF1 enhancer region. 17 Parental DNA sequencing for subjects 2 and 6 revealed that both the c.146C>A point mutation and the 1.5 Mb CNV deletion arose de novo. No point mutations or CNV deletions involving FOXF1 were identified in subject 3 who had a sibling with ACDMPV, nor in subject 5.
Explant Histology
All 6 lung explants demonstrated the histologic features diagnostic of ACDMPV (Table III and Figure) . The main findings of deficient capillarization and malpositioned pulmonary veins were focal or patchy as compared with infants with classic ACDMPV (Table IV) . All explants demonstrated moderate to marked medial wall thickening of the small pulmonary arteries and arterioles consistent with the clinical histories of pulmonary hypertension. Lymphangiectasis was present in all explant specimens, including subjects 2 and 6, who were not mechanically ventilated at the time of transplantation. Although lobular maldevelopment with deficient alveolarization was diffuse and readily observed in all infants with classic ACDMPV, the explanted lungs of infants with atypical ACDMPV were more heterogeneous. Two of the explants (subjects 3 and 4) had focal areas with definite deficient alveolarization as well as other areas suggestive of maldevelopment. The other 4 atypical ACDMPV explants had focal areas suggestive of deficient alveolarization. Findings consistent with secondary remodeling were also present in the explanted lungs. There were no obvious differences in explant histopathology among infants with or without FOXF1 point mutations or CNV deletions.
Discussion
Delayed presentations of ACDMPV after the neonatal period [4] [5] [6] [7] [8] [9] or with prolonged survival 8, 9, 23, 24 suggest biologically and developmentally diverse mechanisms contribute to disease presentation. In contrast with the classic neonatal presentation of ACDMPV, only 3 subjects (1, 2, and 6) had respiratory symptoms in the newborn period. Two infants (subjects 1 and 6) were treated with nasal cannula oxygen that was discontinued by 3 weeks of life, and then presented with fulminant symptoms at 3 and 7 months, respectively. The third infant (subject 2) had a persistent oxygen requirement and echocardiographic evidence of pulmonary hypertension that prompted diagnos- Histologic assessment focused on areas of congested, noncollapsed lung, in which architecture and capillaries were well-visualized.
March 2018
ORIGINAL ARTICLES tic lung biopsy at 1 month of age. Although this infant had the earliest presentation, biopsy, and diagnosis, he underwent lung transplant at the oldest age (DOL 633) and required the least respiratory support at the time of transplantation (supplemental nasal cannula oxygen and nitric oxide). His explant histology demonstrated focal findings, which may have contributed to his comparatively indolent course. The remaining 3 subjects had no significant respiratory symptoms within the first 2-3 months of life, including the infant with a family history of ACDMPV (subject 3). Because of the wide variability and timing of presentations, atypical ACDMPV should remain in the differential diagnosis of any infant with hypoxemia and idiopathic pulmonary hypertension.
The histopathologic characteristics of capillary dysplasia and misaligned pulmonary veins ranged from focal to patchy in the explanted lungs, but did not correlate with the age of fulminant presentation or the presence of FOXF1 point mutations or CNV deletion. Although our study is limited in that explant histology may be confounded by differences in pretransplant treatment (mechanical ventilation, prolonged oxygen exposure) and chronologic age, the nonuniformity of histopathologic characteristics suggests that disruption of lung development in this disease is location specific and may be influenced by the local cellular and growth factor milieu. It is important to note that all 6 explants had areas of lung with normal capillary loops, a finding that illustrates the 25 Failure to identify FOXF1 point mutations or CNV deletions in 2 of the 5 subjects tested suggests that other genes may contribute to or modify the ACDMPV phenotype. 10 All 6 infants in our series had clinical and histologic evidence for significant pulmonary hypertension. Medial wall hypertrophy, although present, was less pronounced among the 3 infants with classic ACDMPV (Table IV) . It is unclear whether this difference reflects a primary process related to endothelial cell proliferation or is secondary to therapies or chronic/ prolonged disruption of the pulmonary vascular bed. For 5 atypical ACDMPV infants, the severity of their pulmonary hypertension contributed to the eventual need for intensive medical and mechanical respiratory support before transplantation. Presumably, their pulmonary hypertension resulted from an anatomically fixed, decreased number of pulmonary capillaries within the alveolar epithelium, misaligned pulmonary veins, and abnormal lobular development. Although neonates with classic ACDMPV typically have transient but nonsustained responses to pulmonary vasodilators, 1 3 atypical ACDMPV infants (subjects 2, 4, and 6) demonstrated a reduction in pulmonary resistance with inhaled nitric oxide administration during cardiac catheterization, and successful treatment of all 6 infants with pulmonary vasodilators suggests pharmacologically reversible components of pulmonary hypertension. However, our study was not specifically designed to determine the effects of these therapies thereby limiting this finding. The usefulness of these medications among infants with atypical ACDMPV compared with classic ACDMPV may reflect in part the heterogeneous nature of their disease or the diversity of the underlying biologic or developmental mechanisms.
Five infants in our series had chest CT scans that demonstrated findings of ILD with ground glass opacities and septal thickening. In contrast with infants with atypical ACDMPV, infants with idiopathic primary pulmonary hypertension typically are not hypoxemic without a significant intracardiac shunt and usually do not have abnormalities of the pulmonary parenchyma on chest CT. 26 Infants with biallelic loss of function mutations in surfactant proteins (SFTPB, ABCA3) typically present with severe neonatal respiratory distress syndrome and have chest radiograph findings consistent with surfactant deficiency. 27 Infants with dominant point mutations in SFTPC or missense variants in ABCA3 can present beyond the newborn period with childhood ILD and pulmonary hypertension, which when present, is associated with increased mortality. 28 The presentation of pulmonary venoocclusive disease and pulmonary capillary hemangiomatosis with hypoxemia, pulmonary hypertension, and abnormal CT scan results (patchy centrilobular pattern of ground glass opacities, pavement appearance to lobules) can make differentiation from ACDMPV potentially difficult. Owing to the wide variability and timing of presentations, atypical ACDMPV should remain in the differential diagnosis of any infant with hypoxemia and idiopathic pulmonary hypertension including those with chest CT findings of ILD; clinical testing of FOFX1 in these patients may be diagnostic.
Although lung transplantation is a recognized therapy for children with end-stage lung disease, 29 successful transplantation for ACDMPV is limited to 2 case reports. 17, 19 In a large international registry, the median survival of all children after lung transplant is 5.3 years, with infants having a slightly better median survival of 6.4 years. 30 The mortality and outcomes of the patients transplanted for ACDMPV in our series are comparable with infants and children transplanted for genetic disorders of surfactant metabolism at our institution. 31 Prospective studies such as those being performed through the Childhood Interstitial Lung Disease Research Network are needed to identify genetic, therapeutic, or environmental factors that contribute to delayed presentation or prolonged survival without transplantation. 
